AbbVie annual return on assets (roa)
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
AbbVie Return on Assets (ROA) Growth & History (ABBV)
AbbVie's return on assets (roa) was 3.14% for fiscal 2025.
View full AbbVie company overviewAbbVie annual return on assets (roa) history
| Fiscal year | Period ended | Return on assets (ROA) | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 3.14% | −0.03 pp |
| 2024 | 2024-12-31 | 3.17% | −0.39 pp |
| 2023 | 2023-12-31 | 3.56% | −4.74 pp |
| 2022 | 2022-12-31 | 8.30% | +0.53 pp |
| 2021 | 2021-12-31 | 7.77% | +3.92 pp |
| 2020 | 2020-12-31 | 3.85% | −6.77 pp |
| 2019 | 2019-12-31 | 10.62% | +1.88 pp |
| 2018 | 2018-12-31 | 8.74% | +0.98 pp |
| 2017 | 2017-12-31 | 7.76% | −2.24 pp |
| 2016 | 2016-12-31 | 9.99% | −2.78 pp |
| 2015 | 2015-12-31 | 12.77% | +6.51 pp |
| 2014 | 2014-12-31 | 6.26% | — |
AbbVie quarterly return on assets (roa)
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on assets (ROA) | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 4.63% | +1.94 pp |
| Q1 2026 | 2026-03-31 | 2.67% | −0.28 pp |
| Q4 2025 | 2025-12-31 | 3.14% | −0.03 pp |
| Q3 2025 | 2025-09-30 | 1.72% | −1.94 pp |
| Q2 2025 | 2025-06-30 | 2.70% | −1.15 pp |
| Q1 2025 | 2025-03-31 | 2.94% | −1.29 pp |
| Q4 2024 | 2024-12-31 | 3.17% | −0.39 pp |
| Q3 2024 | 2024-09-30 | 3.66% | −1.03 pp |
| Q2 2024 | 2024-06-30 | 3.85% | −2.39 pp |
| Q1 2024 | 2024-03-31 | 4.23% | −1.23 pp |
| Q4 2023 | 2023-12-31 | 3.56% | −4.74 pp |
| Q3 2023 | 2023-09-30 | 4.69% | −4.55 pp |
| Q2 2023 | 2023-06-30 | 6.24% | −2.44 pp |
| Q1 2023 | 2023-03-31 | 5.46% | −3.04 pp |
| Q4 2022 | 2022-12-31 | 8.30% | +0.53 pp |
| Q3 2022 | 2022-09-30 | 9.24% | +4.19 pp |
| Q2 2022 | 2022-06-30 | 8.68% | +4.20 pp |
| Q1 2022 | 2022-03-31 | 8.50% | +4.23 pp |
| Q4 2021 | 2021-12-31 | 7.77% | +3.92 pp |
| Q3 2021 | 2021-09-30 | 5.05% | −2.01 pp |
| Q2 2021 | 2021-06-30 | 4.48% | −2.25 pp |
| Q1 2021 | 2021-03-31 | 4.27% | −7.13 pp |
| Q4 2020 | 2020-12-31 | 3.85% | −6.77 pp |
| Q3 2020 | 2020-09-30 | 7.06% | +1.88 pp |
| Q2 2020 | 2020-06-30 | 6.73% | −0.20 pp |
| Q1 2020 | 2020-03-31 | 11.40% | +2.90 pp |
| Q4 2019 | 2019-12-31 | 10.62% | +1.88 pp |
| Q3 2019 | 2019-09-30 | 5.18% | −6.02 pp |
| Q2 2019 | 2019-06-30 | 6.93% | −3.09 pp |
| Q1 2019 | 2019-03-31 | 8.50% | −0.95 pp |
| Q4 2018 | 2018-12-31 | 8.74% | +0.98 pp |
| Q3 2018 · Sep 30 | 2018-09-30 | 11.21% | +1.39 pp |
| Q2 2018 | 2018-06-30 | 10.03% | +0.17 pp |
| Q1 2018 | 2018-03-31 | 9.45% | −1.12 pp |
| Q4 2017 | 2017-12-31 | 7.76% | −2.24 pp |
| Q3 2017 | 2017-09-30 | 9.82% | −0.20 pp |
| Q2 2017 | 2017-06-30 | 9.86% | +0.41 pp |
| Q1 2017 | 2017-03-31 | 10.57% | −3.05 pp |
| Q4 2016 | 2016-12-31 | 9.99% | −2.78 pp |
| Q3 2016 | 2016-09-30 | 10.01% | — |
| Q2 2016 | 2016-06-30 | 9.45% | — |
| Q1 2016 | 2016-03-31 | 13.62% | — |
| Q4 2015 | 2015-12-31 | 12.77% | — |
AbbVie return on assets (roa) trends
Over the last five fiscal years, AbbVie's return on assets (roa) decreased from 3.85% to 3.14%, a change of −0.71 percentage points. The latest reported quarter, Q2 2026, shows 4.63%.
About the metric
What return on assets means
Return on assets measures profit relative to the assets used to generate it. It can help compare operating efficiency over time, although normal ROA differs substantially between asset-light and asset-intensive industries.
Calculation and source
How return on assets is calculated
TickerStat calculates annual ROA as reported net income divided by average total assets. Quarterly observations use trailing-12-month net income and average assets over the corresponding one-year period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review AbbVie source filings ↗Community posts
FDA clears at-home Skyrizi induction for Crohn’s disease
AbbVie ($ABBV) received FDA approval for subcutaneous induction dosing of Skyrizi in adults with moderately to severely active Crohn’s disease. Patients can now begin treatment at home using an on-body injector, extending that delivery opti ...
AbbVie meets pivotal hidradenitis endpoint with lutikizumab
AbbVie ($ABBV) reported that lutikizumab met the main endpoint and all eight ranked secondary endpoints in the Phase 3 INTREPID trial for moderate to severe hidradenitis suppurativa. At week 16, 31.4% of treated patients achieved HiSCR75, c ...
AbbVie’s menstrual-migraine study meets its primary and all ranked secondary goals
AbbVie ($ABBV) reported positive Phase 3 LUNA results for atogepant in menstrual migraine. The study enrolled 468 women and evaluated treatment across three menstrual cycles. Migraine days during the assessed menstrual period fell by 1.20 d ...
